Literature DB >> 25317881

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Martyn E Caplin, Marianne Pavel, Philippe Ruszniewski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25317881     DOI： 10.1056/NEJMc1409757

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  45 in total

1.  Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?

Authors:  Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12       Impact factor: 9.236

Review 2.  Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

Review 3.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 4.  Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila.

Authors:  Vaibhav Rastogi; Devina Singh; Joseph J Mazza; Dipendra Parajuli; Steven H Yale
Journal:  Clin Med Res       Date:  2018-04-12

Review 5.  Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.

Authors:  Javier Molina-Cerrillo; Teresa Alonso-Gordoa; Olga Martínez-Sáez; Enrique Grande
Journal:  Oncologist       Date:  2016-04-22

6.  CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Authors:  Yanji Luo; Jie Chen; Bingqi Shen; Meng Wang; Huasong Cai; Ling Xu; Luohai Chen; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-06-06       Impact factor: 5.315

Review 7.  Peptide Receptor Radiotherapy: Current Approaches and Future Directions.

Authors:  Grace Kong; Rodney J Hicks
Journal:  Curr Treat Options Oncol       Date:  2019-08-29

8.  SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors.

Authors:  Penghui Yang; Xuanlin Huang; Chengcai Lai; Lin Li; Tieling Li; Peide Huang; Songying Ouyang; Jin Yan; Sijie Cheng; Guanglin Lei; Zhaohai Wang; Linxiang Yu; Zhixian Hong; Ruisheng Li; Hui Dong; Cheng Wang; Yinghao Yu; Xuan Wang; Xianghong Li; Liming Wang; Fudong Lv; Ye Yin; Huanming Yang; Jianxun Song; Qiang Gao; Xiliang Wang; Shaogeng Zhang
Journal:  Int J Cancer       Date:  2019-05-17       Impact factor: 7.396

9.  Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.

Authors:  Manuel Weber; Lukas Kessler; Benedikt Schaarschmidt; Wolfgang Peter Fendler; Harald Lahner; Gerald Antoch; Lale Umutlu; Ken Herrmann; Christoph Rischpler
Journal:  BMC Cancer       Date:  2020-04-16       Impact factor: 4.430

Review 10.  Management of pulmonary neuroendocrine tumors.

Authors:  Robert A Ramirez; Aman Chauhan; Juan Gimenez; Katharine E H Thomas; Ioni Kokodis; Brianne A Voros
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.